News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
734,639 Results
Type
Article (49846)
Company Profile (278)
Press Release (684515)
Section
Business (212420)
Career Advice (2123)
Deals (36577)
Drug Delivery (103)
Drug Development (83637)
Employer Resources (173)
FDA (16971)
Job Trends (15712)
News (359459)
Policy (34686)
Tag
2024 BioCapital Digital (7)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (8)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (6)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (5)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2776)
Accelerated approval (4)
Adcomms (23)
Allergies (83)
Alliances (51589)
ALS (87)
Alzheimer's disease (1418)
Antibody-drug conjugate (ADC) (115)
Approvals (16972)
Artificial intelligence (256)
Autoimmune disease (17)
Automation (14)
Bankruptcy (373)
Best Places to Work (12098)
BIOSECURE Act (18)
Biosimilars (103)
Biotechnology (191)
Bladder cancer (60)
Brain cancer (26)
Breast cancer (264)
Cancer (2071)
Cardiovascular disease (172)
Career advice (1775)
Career pathing (30)
CAR-T (143)
Cell therapy (403)
Cervical cancer (21)
Clinical research (67695)
Collaboration (795)
Compensation (469)
Complete response letters (21)
COVID-19 (2711)
CRISPR (36)
C-suite (221)
Cystic fibrosis (99)
Data (2009)
Decentralized trials (2)
Denatured (26)
Depression (45)
Diabetes (256)
Diagnostics (6552)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (115)
Drug pricing (102)
Drug shortages (28)
Duchenne muscular dystrophy (87)
Earnings (88430)
Editorial (34)
Employer branding (21)
Employer resources (147)
Events (116789)
Executive appointments (666)
FDA (18138)
Featured Employer (49)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (712)
Gene editing (101)
Generative AI (24)
Gene therapy (287)
GLP-1 (738)
Government (4654)
Grass and pollen (4)
Guidances (49)
Healthcare (19903)
Huntington's disease (22)
IgA nephropathy (24)
Immunology and inflammation (107)
Indications (27)
Infectious disease (2849)
Inflammatory bowel disease (138)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (87)
Interviews (329)
IPO (16856)
IRA (41)
Job creations (4047)
Job search strategy (1515)
Kidney cancer (9)
Labor market (34)
Layoffs (473)
Leadership (16)
Legal (8465)
Liver cancer (73)
Lung cancer (302)
Lymphoma (135)
Machine learning (4)
Management (58)
Manufacturing (274)
MASH (64)
Medical device (14332)
Medtech (14337)
Mergers & acquisitions (20208)
Metabolic disorders (668)
Multiple sclerosis (74)
NASH (16)
Neurodegenerative disease (91)
Neuropsychiatric disorders (28)
Neuroscience (1928)
NextGen: Class of 2025 (6914)
Non-profit (4738)
Northern California (2475)
Now hiring (37)
Obesity (363)
Opinion (217)
Ovarian cancer (73)
Pain (83)
Pancreatic cancer (77)
Parkinson's disease (143)
Partnered (20)
Patents (208)
Patient recruitment (99)
Peanut (48)
People (60003)
Pharmaceutical (68)
Pharmacy benefit managers (19)
Phase I (21051)
Phase II (29743)
Phase III (22242)
Pipeline (1068)
Podcasts (58)
Policy (116)
Postmarket research (2742)
Preclinical (8945)
Press Release (67)
Prostate cancer (97)
Psychedelics (32)
Radiopharmaceuticals (254)
Rare diseases (371)
Real estate (6301)
Recruiting (65)
Regulatory (23597)
Reports (46)
Research institute (2481)
Resumes & cover letters (365)
Rett syndrome (4)
RNA editing (4)
RSV (41)
Schizophrenia (71)
Series A (122)
Series B (80)
Service/supplier (13)
Sickle cell disease (52)
Southern California (2140)
Special edition (14)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3834)
State (2)
Stomach cancer (14)
Supply chain (63)
Tariffs (11)
The Weekly (30)
United States (21831)
Vaccines (697)
Venture capitalists (38)
Webinars (12)
Weight loss (251)
Women's health (36)
Worklife (15)
Date
Today (119)
Last 7 days (692)
Last 30 days (2747)
Last 365 days (34358)
2025 (8485)
2024 (36126)
2023 (41155)
2022 (52394)
2021 (57110)
2020 (55920)
2019 (48809)
2018 (36960)
2017 (33765)
2016 (33590)
2015 (39621)
2014 (33354)
2013 (28627)
2012 (30893)
2011 (31592)
2010 (29969)
Location
Africa (797)
Alabama (50)
Alaska (7)
Arizona (232)
Arkansas (14)
Asia (40915)
Australia (6748)
California (5642)
Canada (1893)
China (493)
Colorado (259)
Connecticut (272)
Delaware (131)
Europe (88750)
Florida (835)
Georgia (204)
Idaho (61)
Illinois (540)
India (24)
Indiana (299)
Iowa (9)
Japan (144)
Kansas (104)
Kentucky (24)
Louisiana (9)
Maine (61)
Maryland (874)
Massachusetts (4294)
Michigan (215)
Minnesota (386)
Mississippi (2)
Missouri (79)
Montana (27)
Nebraska (25)
Nevada (58)
New Hampshire (67)
New Jersey (1623)
New Mexico (29)
New York (1626)
North Carolina (989)
North Dakota (7)
Northern California (2475)
Ohio (194)
Oklahoma (14)
Oregon (34)
Pennsylvania (1271)
Puerto Rico (9)
Rhode Island (29)
South America (1185)
South Carolina (19)
South Dakota (1)
Southern California (2140)
Tennessee (97)
Texas (848)
Utah (168)
Virginia (135)
Washington D.C. (61)
Washington State (534)
West Virginia (3)
Wisconsin (50)
734,639 Results for "ela medical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Electra Therapeutics Presents Late-Breaking Clinical Data at EHA2024 from Ongoing Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced the presentation of clinical data for ELA026 in secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition.
June 16, 2024
·
5 min read
Biotech Bay
Electra Therapeutics to Present ELA026 Clinical Data in Late-Breaking Oral Session at the 2024 European Hematology Association (EHA) Congress
Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today that clinical data for its lead drug candidate, ELA026, will be presented as one of five selected abstracts in a late-breaking oral session at the European Hematology Association (EHA) Congress.
June 3, 2024
·
2 min read
Press Releases
Electra Therapeutics Receives FDA Fast Track Designation for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
November 4, 2024
·
2 min read
Press Releases
Electra Therapeutics Receives FDA Orphan Drug Designation for ELA026 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
October 30, 2024
·
2 min read
Press Releases
Electra Therapeutics to Present Clinical Results for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in an Oral Session at ASH 2024
November 5, 2024
·
3 min read
Press Releases
Electra Therapeutics Presents Positive Clinical Results From Completed Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in an Oral Session at ASH 2024
December 9, 2024
·
6 min read
Biotech Bay
Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)
Electra Therapeutics, Inc. announced the presentation of the first clinical data for ELA026, the company’s lead candidate in development for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening inflammatory disease.
December 11, 2023
·
4 min read
Biotech Bay
Electra Therapeutics to Present Clinical Data for ELA026 at the American Society of Hematology (ASH) 2023 Annual Meeting
Electra Therapeutics, Inc announced today that the company will present the initial clinical data for its lead drug candidate, ELA026, in a poster at the American Society of Hematology (ASH) annual meeting being held in San Diego, California, December 9-12, 2023.
November 2, 2023
·
2 min read
Press Releases
Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025
April 1, 2025
·
1 min read
Press Releases
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE
April 3, 2025
·
5 min read
1 of 73,464
Next
